Is 6 Months of Neuroleptic Withdrawal Sufficient to Distinguish Drug-Induced Parkinsonism From Parkinson's Disease?

REFERENCES

• Ayd FJ. A survey of drug induced extrapyramidal reactions. JAMA. 1961;175:1054–60.
   PubMedGoogle Scholar
• Mindham RHS. Assessment of drug-induced extrapyramidal reactions and of drugs given for their control. Br J Clin Pharmacol. 1976;2(suppl):395–400.
   Google Scholar
• McLolland HA. Discussion on assessment of drug-induced extrapyramidal reactions. Br J Psychiatry. 1978;132:27–30.
   Google Scholar
• Hansen TE, Brown WL, Weigel RM, Casey DE. Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. Gen Hosp Psychiatry. 1992;14:340–4.
   PubMedGoogle Scholar
• Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P. Reversible drug-induced parkinsonism: clinicopathologic study of two cases. Arch Neurol. 1982;39:644–6.
   PubMedGoogle Scholar
• Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry. 1988;51:850–4.
   PubMedGoogle Scholar
• Van Gerpen JA. Drug-induced parkinsonism. Neurologist. 2002;8:363–70.
   PubMedGoogle Scholar
• Chabolla DR, Maraganore DM, Ahlskog JE, O'Brien PC, Rocca WA. Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmstrd County, Minnesota. Mayo Clin Proc. 1998;73:724–7.
   PubMedGoogle Scholar
• Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet. 1984;324(8411):1082–3.
   Google Scholar
• Thanvi B, Treadwell S. Drug-induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J. 2009;85:322–6.
   PubMedGoogle Scholar
• Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J. 2011;87:132–41.
   PubMedGoogle Scholar
• Fukunishi I, Kitaoka T, Shirai T, Kino K, Kanematsu E, Sato Y. A hemodialysis patient with trazodone-induced parkinsonism. Nephron. 2002;90(2):222–3.
   PubMedGoogle Scholar
• Albanese A, Rossi P, Altavista MC. Can trazodone induce parkinsonism? Clin Pharmacol. 1988;11(2):180–2.
   Google Scholar
• Di Rocco A, Brannan T, Prikhojan A, Yahr MD. Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm. 1998;105(2–3):247–51.
   PubMedGoogle Scholar
• Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clinic Psychiatry. 1996;57(10):449–54
   PubMedGoogle Scholar
• Grosset DG, Grosset KA, Okun MS, Fernandez HH. Clinician's desk reference Parkinson's disease. London: Manson Publishing Ltd., 2009.
   Google Scholar
• Morgan J, Sethi KD. Differential diagnosis. In: Pahwa R, Lyons KE, editors. Handbook of Parkinson's disease. 4th ed. New York: Informa Healthcare, 2007, p. 29–47.
   Google Scholar
• Wolters E, Van Laar T, Berendse H. Parkinsonism and related disorders. Amsterdam: VU University Press, 2007.
   Google Scholar
• Kompoliti K, Horn SS. Drug-induced and iatrogenic neurological disorders. In: Goetz CG, editor. Textbook of clinical neurology. 3rd ed. Philadelphia, PA: Saunders, 2007.
   Google Scholar
• DeKosky ST, Kaufer DI, Hamilton RL, Wolk DA, Lopez OL. The dementias. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, editors. Neurology in clinical practice. 5th ed. Philadelphia, PA: Butterworth-Heinemann Elsevier. 2007.
   Google Scholar
• Ondo WG. Other movement disorders. In: Chaudhuri KR, Ondo WG, editors. Movement disorders in clinical practice. London: Springer-Verlag, 2010. p. 89–106.
   Google Scholar
• Chaudhuri KR, Nott J. Drug-induced parkinsonism. In: Sethi KD, editor. Drug-induced movement disorders. New York: Marcel Dekker, 2004. p. 61–75.
   Google Scholar
• Chen JJ, Swope DM. Drug-induced diseases: prevention, detection, and management. In: Tisdale J, Miller D, editors. Movement disorders. 2nd ed. Bethesda: American Society of Health-System Pharmacists, 2010. p. 211–35.
   Google Scholar
• Yamamoto M, Ujike H, Ogawa N. Metoclopramide-induced parkinsonism. Clin Neuropharmacol. 1987;10(3):287–9.
   PubMedGoogle Scholar
• Miletic V, Relja M. Citalopram-induced parkinsonian syndrome. Clin Neuropharmacol. 2011;34:92–3.
   PubMedGoogle Scholar
• Alverez MVG, Evidente VGH, Driver-Dunckley ED. Differentiating Parkinson's disease from other parkinsonian disorders. Semin Neurol. 2007;27(4):356–62.
   PubMedGoogle Scholar
• Alvarez MVG, Evidente VGH. Understanding drug-induced parkinsonism: separating pearls from oysters. Neurology. 2008;70:e32–4.
   PubMedGoogle Scholar
• Gwinn KA, Caviness JN. Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord. 1997;12:119–21.
   PubMedGoogle Scholar
• Scharre DW, Mahler ME. Parkinson's disease: making the diagnosis, selecting drug therapies. Geriatrics. 1994;49(10):14–6, 20–3.
   Google Scholar
• Zesiewicz TA, Sanchez-Ramos J, Sullivan KL, Hauser R. Levetiracetam-induced parkinsonism in a Huntington disease patient. Clin Neuropharmacol. 2005;28(4): 188–90.
   PubMedGoogle Scholar
• Gershanik OS. Drug-induced parkinsonism in the aged: recognition and prevention. Drugs Aging. 1994;5(2):127–32.
   PubMedGoogle Scholar